| Ticker: IMII | 4360 Northlake Boulevard, Suite 214 | |
| Exchange: NASDAQ-National Market | Palm Beach Gardens, Florida 33410 | |
| Industry: Manufacturing | (407) 627-0344 |
| Type of Shares: | Common Shares | Filing Date: | 1/29/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 3/21/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $10.00 - $12.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $11.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.77 | |
| Offering Amount: | $33,000,000 | Selling: | $0.46 | |
| Expenses: | $990,000 | Reallowance: | $0.10 | |
| Shares Out After: | 10,191,435 |
| Manager | Tier | Phone |
| Smith Barney Inc. | Lead Manager | (718) 921-8473 |
| Pacific Crest Securities Inc. | Co-manager | (503) 248-0721 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $1.39 | Assets: | $2.71 | ||
| Net Income: | -$3.99 | Liabilities: | $3.93 | ||
| EPS: | -$0.64 | Equity: | -$1.23 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The Company has developed and is marketing the Micro21 System, an intelligent automated microscope system, for diagnostic use in hospital, commercial reference and physician group practice laboratories. The Micro21 System is designed to automate a broad range of manual microscopic procedures, potentially enabling the laboratory to reduce costs and exposure to liabilities, enhance analytical accuracy and consistency, increase the productivity of medical technologists and improve patient care. According to industry sources, 1.3 billion manual microscopic procedures are performed manually by trained medical technologists and, consequently, are costly, time consuming and subject to varying degrees of accuracy and consistency. These procedures, which are performed to assist in the diagnosis of various diseases, including most cancer, AIDS and other sexually transmitted diseases, anemia, infections and genetic disorders, remain the last major segment of the clinical laboratory to be automated. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development of Micro21 System enhancements and additional procedures; repayment of debt and other obligations; working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.